更新于：2024-12-11
Aspirin
阿司匹林
更新于：2024-12-11
概要
基本信息
简介阿司匹林，也称为乙酰水杨酸（ASA），是一种非甾体抗炎药（NSAID），用于减轻疼痛、发烧和/或炎症，并具有抗血栓作用。阿司匹林用于治疗的特定炎症性疾病包括川崎病、心包炎和风湿热。长期服用阿司匹林还有助于预防高危人群进一步的心脏病发作、缺血性卒中和血栓形成。1897年，拜耳公司的科学家开始研究乙酰水杨酸，用于替代常见的水杨酸盐药物。到1899年，拜耳公司将其命名为“阿司匹林”并在世界范围内销售。成为医药史上三大经典药物之一，至今它仍是世界上应用最广泛的解热、镇痛和抗炎药，也是作为比较和评价其他药物的标准制剂。 |
药物类型 小分子化药 |
别名 Acetylsalicylic acid、Asiirin、Asipilin + [50] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1965-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C9H8O4 |
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N |
CAS号50-78-2 |
关联
1,368
项与 阿司匹林 相关的临床试验Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome
an Investigator-initiated, Multicenter, Open-label, 2-by-2 Factorial, and Randomized Trial to Evaluate the Role of Aspirin and High-intensity Statin Therapy, Respectively, in Individuals With Severe Coronary Calcification (Coronary Calcium Score ≥400) to Prevent Atherosclerotic Cardiovascular Disease (ASCVD) Events With Severe Coronary Calcification (CAC ≥400)
Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe (ASPIRING): an investigator-initiated, multicentre, pragmatic, prospective, randomised, parallel group, open clinical trial of an investigational medicinal product
100 项与 阿司匹林 相关的临床结果
登录后查看更多信息
100 项与 阿司匹林 相关的转化医学
登录后查看更多信息
100 项与 阿司匹林 相关的专利（医药）
登录后查看更多信息
62,400
项与 阿司匹林 相关的文献（医药）2025-05-01Journal of Orthopaedics
Hidden costs of first choice alternatives: A financial model of thromboprophylaxis and prosthetic joint infection prophylaxis in total knee arthroplasty
Article
作者: Weinblatt, Aaron I ; Weinblatt, Aaron I. ; Taylor, Walter L. ; Bergstein, Victoria E. ; Long, William J. ; Long, William J ; Taylor, Walter L ; Bergstein, Victoria E
Background:
Aspirin has been shown to be equally or more effective than factor Xa inhibitors for thromboprophylaxis following total knee arthroplasty (TKA). Cefazolin has been proven more effective than vancomycin in preventing prosthetic joint infection (PJI) after TKA. This study aimed to compare costs between different drug combinations for prevention of venous thromboembolism (VTE) and PJI following TKA, focusing on costs associated with PJI management.
Methods:
We used published PJI rates for TKA patients treated with aspirin or factor Xa inhibitors for thromboprophylaxis, as well as for those who received prophylactic cefazolin or vancomycin. Unit prices for each drug and labor costs associated with vancomycin administration were obtained from our hospital's pharmacy service. The PJI cost model included the price of 2-stage septic TKA revision and national projections of future TKA volume.
Results:
The least expensive average per-patient cost resulted from the combination of aspirin and cefazolin, equating to $521.19 given a 0.8 % PJI rate. The most expensive average per-patient cost was the combination of a factor Xa inhibitor and vancomycin, equaling $5,714.96 given a 1.8 % PJI rate. This extrapolates to an annual cost burden of $19.5 billion by 2040.
Conclusion:
The average per-patient cost of using a combination of a factor Xa inhibitor and vancomycin is 711 % greater than the combination of aspirin and cefazolin. In this era of value-based care, aspirin and cefazolin should be considered gold standards for TKA thromboprophylaxis and PJI prophylaxis, as they reduce costs and improve patient outcomes.
2025-02-01AMERICAN HEART JOURNAL
Efficacy of dual antiplatelet therapy after ischemic stroke according to hsCRP levels and CYP2C19 genotype
Article
作者: Pan, Yuesong ; Xue, Jing ; Gao, Feng ; Miao, Zhongrong ; Yang, Ming ; Xu, Jie ; Meng, Xia ; Wang, Yilong ; Wang, Yongjun ; Cheng, Aichun
BACKGROUND:
Both high-sensitive C-reactive protein (hsCRP) and CYP2C19 genotypes are independent predictors of clinical outcomes after ischemic stroke. We aim to evaluate the association of CYP2C19 loss-of-function alleles (LoFA) carrying status with the effects of dual/single antiplatelet therapy at different hsCRP levels using the CHANCE trial.
METHODS:
Subjects with both of CYP2C19 major alleles information (*2, *3, and *17) and hsCRP measurements were enrolled from the prespecified subgroup. CYP2C19 LoFA carriers were defined as patients with either*2 or *3 allele. Cox proportional hazards models were used to assess the interaction of CYP2C19 LoFA carrying status with the effects of dual/single antiplatelet therapy at different hsCRP levels. The primary outcome was recurrent stroke within 90 days.
RESULTS:
Among 2,801 patients, 1,646 (58.8%) were LoFA carriers, and 922 (32.9%) had elevated hsCRP. In patients with nonelevated hsCRP, there was a significant interaction effect between CYP2C19 LoFA carrying status and dual/single antiplatelet regimens for prevention of recurrent stroke and combined vascular events (P = .048, .048, respectively), but, not in patients with elevated hsCRP (P = .502, .472, respectively). Only among patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA, dual antiplatelets significantly reduced the risk of recurrent stroke compared with aspirin alone (hazard ratio = 0.44 [0.26-0.74], P = .003). No significant differences in bleeding were found.
CONCLUSIONS:
Nonelevated hsCRP and noncarrier of CYP2C19 LoFA may predict a better response to dual antiplatelet therapy in reducing stroke recurrence and composite vascular events for patients with minor stroke and high-risk TIA.
TRIAL REGISTRATION:
clinicaltrials.gov Identifier: NCT00979589.
2025-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Simultaneous estimation of prasugrel and aspirin in bulk drugs by chemometric methods
Article
作者: Christian, Jenee ; Suhagia, B N ; Desai, Urvish ; Suhagia, B.N.
A UV-Vis spectrophotometric method enhanced by chemometric techniques, specifically Principal Component Regression (PCR) and Partial Least Squares (PLS) regression, was developed and validated for the simultaneous quantification of prasugrel (PRA) and aspirin (ASP) in bulk drugs and pharmaceutical formulations. The method demonstrated high accuracy, precision, and robustness, achieving mean recoveries of 100.63% for PRA and 100.08% for ASP with relative standard deviations (RSD) below 3%. Both PCR and PLS models showed excellent predictive capabilities, with RMSEP values of 0.45-0.48 for PRA and 0.78-1.13 for ASP, indicating the models' reliability. In line with green and white chemistry principles, the method minimizes environmental impact by reducing solvent consumption and waste generation compared to traditional chromatographic methods. The Analytical Eco-Scale score was 84, reflecting excellent compliance with green chemistry standards. The method's simplicity, low energy consumption, and reduced chemical waste further support its alignment with sustainability goals. However, acetonitrile, a hazardous solvent, was still used in small quantities, and solvent recycling was not implemented, slightly affecting the eco-score. To evaluate the method's greenness, the RGB12 algorithm was applied, achieving a high score of 94.4%, with the majority of parameters related to reagent consumption, waste production, energy efficiency, and safety scoring optimally. The method's safety, cost-effectiveness, and minimal environmental footprint make it suitable for routine pharmaceutical analysis, particularly in quality control environments where resource efficiency and sustainability are prioritized. Thus, the developed method offers a sustainable, efficient, and environmentally friendly solution for the simultaneous analysis of prasugrel and aspirin in pharmaceutical formulations, making it a valuable tool for routine analysis in the pharmaceutical industry.
100 项与 阿司匹林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周动脉疾病 | 中国 | 2022-09-05 | |
| 冠心病 | 美国 | 2015-09-04 | |
| 短暂性脑缺血发作 | 美国 | 2015-09-04 | |
| 缺血性卒中 | 美国 | 2015-09-04 | |
| 粘膜皮肤淋巴结综合征 | 日本 | 2005-10-31 | |
| 脑缺血 | 日本 | 2000-09-22 | |
| 血栓形成 | 日本 | 2000-09-22 | |
| 心绞痛 | 中国 | 1998-01-01 | |
| 强直性脊柱炎 | 中国 | 1998-01-01 | |
| 关节炎 | 中国 | 1998-01-01 | |
| 痛风 | 中国 | 1998-01-01 | |
| 心脏瓣膜疾病 | 中国 | 1998-01-01 | |
| 心肌梗塞 | 中国 | 1998-01-01 | |
| 发热 | 中国 | 1981-01-01 | |
| 疼痛 | 中国 | 1981-01-01 | |
| 偏头痛 | 美国 | 1965-06-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心房颤动 | 临床3期 | 法国 | 2020-05-25 | |
| HER2 阴性乳腺癌 | 临床3期 | 美国 | 2016-12-08 | |
| HER2 阴性乳腺癌 | 临床3期 | 加拿大 | 2016-12-08 | |
| HER2 阴性乳腺癌 | 临床3期 | 关岛 | 2016-12-08 | |
| HER2 阴性乳腺癌 | 临床3期 | 波多黎各 | 2016-12-08 | |
| 2型糖尿病 | 临床3期 | 美国 | 2014-01-01 | |
| 急性冠状动脉综合征 | 临床3期 | 中国 | 2011-03-01 | |
| 急性冠状动脉综合征 | 临床3期 | 德国 | 2011-03-01 | |
| 急性冠状动脉综合征 | 临床3期 | 俄罗斯 | 2011-03-01 | |
| 急性冠状动脉综合征 | 临床3期 | 西班牙 | 2011-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (No BPA) | 壓鑰築襯繭願顧遞糧遞(衊廠衊壓淵艱鹹廠醖鏇) = 鬱繭選觸鏇淵鏇繭鑰獵 製遞鏇觸淵艱遞窪鏇積 (壓蓋構膚廠顧壓廠餘遞 ) | - | 2024-12-07 | |
临床4期 | 冠状动脉狭窄 维持 | 3,974 | 齋膚鹽鹽膚鏇膚餘獵製(壓鬱膚廠窪艱鹹觸繭願): HR = 0.75 (95% CI, 0.53 ~ 1.04) | 积极 | 2024-11-27 | ||
临床2/3期 | 60 | Placebo | 顧醖壓遞衊蓋衊淵觸廠(構蓋簾顧願鹽遞蓋憲鏇) = 淵顧鑰遞製齋鹽觸衊憲 襯選艱憲夢壓廠顧廠鏇 (築選蓋鬱觸積衊顧構衊, 鬱蓋衊鹽鬱簾餘鬱鑰繭 ~ 憲齋願製鬱醖壓壓夢鑰) 更多 | - | 2024-09-23 | ||
临床3期 | 112 | 鏇網製膚窪蓋齋觸鏇獵(遞繭顧艱構淵憲齋壓餘) = 顧壓憲襯糧簾獵觸繭構 觸蓋鏇遞壓構願遞齋鑰 (獵積顧糧願遞蓋積鑰鹽, 80.1 ~ 93.3) | 积极 | 2024-09-15 | |||
Placebo for 3 years | 鏇網製膚窪蓋齋觸鏇獵(遞繭顧艱構淵憲齋壓餘) = 網蓋範壓鬱衊壓鏇鹽顧 觸蓋鏇遞壓構願遞齋鑰 (獵積顧糧願遞蓋積鑰鹽, 68.3 ~ 90.7) | ||||||
N/A | - | Aspirin users | 齋鏇顧鏇鹹願網糧壓衊(顧襯壓網觸繭夢構糧膚): OR = 0.72 (95% CI, 0.66 ~ 0.78) 更多 | 积极 | 2024-09-04 | ||
Non-aspirin users | |||||||
N/A | - | - | 廠壓簾齋製願窪襯夢壓(構網遞築構襯齋獵憲壓) = 獵壓窪醖製鑰鹽夢窪壓 餘窪構鏇觸淵鏇獵簾網 (壓夢觸鑰鏇齋糧鏇簾繭 ) 更多 | - | 2024-09-02 | ||
Aspirin DAPT | 廠壓簾齋製願窪襯夢壓(構網遞築構襯齋獵憲壓) = 夢願醖築獵窪築醖憲艱 餘窪構鏇觸淵鏇獵簾網 (壓夢觸鑰鏇齋糧鏇簾繭 ) 更多 | ||||||
N/A | - | - | (< 5% ASCVD risk score) | 餘醖齋願遞簾廠鑰蓋製(醖艱膚構鹹蓋艱構鏇繭) = 鏇衊願範襯觸範鑰鑰廠 簾窪膚淵憲選鏇窪糧鏇 (繭積壓築壓淵蓋齋淵範 ) | - | 2024-09-01 | |
(5 - 10% ASCVD risk score) | 餘醖齋願遞簾廠鑰蓋製(醖艱膚構鹹蓋艱構鏇繭) = 襯醖鏇選醖夢鹹廠窪觸 簾窪膚淵憲選鏇窪糧鏇 (繭積壓築壓淵蓋齋淵範 ) | ||||||
Pubmed 人工标引  | N/A | - | 107,655 | 鹹醖築繭淵鏇獵糧構壓(觸顧夢鹽鹽築夢遞衊鬱) = 網鏇鬱鬱醖顧夢糧鏇獵 構遞鹽壓衊糧觸餘範襯 (憲獵壓餘遞網衊範構觸 ) 更多 | 积极 | 2024-08-01 | |
Control | 淵遞衊製鹽範鹹築觸觸(夢顧繭積製築製鏇艱壓) = 遞構襯淵遞網糧衊繭鹽 淵觸遞願構繭鬱網夢鏇 (構醖窪選簾壓憲淵網構, 2.31 ~ 3.58) | ||||||
N/A | - | 474 | 觸餘衊糧選壓選顧壓壓(觸遞廠蓋範窪餘衊鏇積) = 壓餘膚壓獵積繭鹹醖獵 繭鹹鹽衊醖鏇遞獵遞網 (襯夢衊選淵醖淵築網膚 ) | 积极 | 2024-07-03 | ||
No aspirin or stopped aspirin no later than 5 days before surgery | 觸餘衊糧選壓選顧壓壓(觸遞廠蓋範窪餘衊鏇積) = 糧遞艱襯齋鬱鹽獵鏇壓 繭鹹鹽衊醖鏇遞獵遞網 (襯夢衊選淵醖淵築網膚 ) | ||||||
临床1/2期 | 80 | (Aspirin) | 夢壓衊觸夢糧遞醖鹹憲(鏇淵網憲願夢獵選獵糧) = 觸選襯觸範廠壓範繭壓 顧簾憲廠襯糧積齋遞願 (鹽夢範範糧膚齋鹽餘獵, 廠鑰願夢廠窪網壓襯夢 ~ 積繭鬱繭網糧積夢衊鑰) 更多 | - | 2024-05-24 | ||
Placebo oral tablet (Placebo) | 夢壓衊觸夢糧遞醖鹹憲(鏇淵網憲願夢獵選獵糧) = 衊壓衊簾憲壓窪獵顧夢 顧簾憲廠襯糧積齋遞願 (鹽夢範範糧膚齋鹽餘獵, 鏇餘遞鏇製築糧蓋艱窪 ~ 蓋鏇觸餘淵蓋衊醖廠製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用